IGC Pharma targets commercial rollout of PRISM layer for Alzheimer’s risk assessment and cognitive monitoring
IGC•IGC Pharma launched PRISM and plans to commercialize it through B2B, B2B2C and online channels for clinical and consumer use. The company said its CALMA Phase 2 trial of IGC-AD1 remains on track for topline results in Q4 2026.
1. PRISM commercialization plans
IGC Pharma launched PRISM to move its Alzheimer’s AI from risk prediction into clinical and consumer workflows. The company is targeting providers, memory clinics, drugmakers, trial sponsors and insurers through B2B, B2B2C and online channels. PRISM is slated to support risk stratification, cognitive monitoring, trial optimization and patient engagement. IGC Pharma plans to pair PRISM with MINT-AD and is advancing AHA to speed Alzheimer’s dataset harmonization. Its CALMA Phase 2 trial of IGC-AD1 remains on track for topline results in Q4 2026.
